Zevra Therapeutics Inc (ZVRA)
4.86
+0.06
(+1.25%)
USD |
NASDAQ |
May 15, 14:48
Zevra Therapeutics Debt to Equity Ratio: 0.8808 for March 31, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.8808 |
| December 31, 2023 | 0.6913 |
| September 30, 2023 | 0.6503 |
| June 30, 2023 | 0.1855 |
| March 31, 2023 | 0.1809 |
| December 31, 2022 | 0.1704 |
| September 30, 2022 | 0.1365 |
| June 30, 2022 | 0.129 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| Date | Value |
|---|---|
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.0093 |
| December 31, 2020 | -1.030 |
| September 30, 2020 | -1.070 |
| June 30, 2020 | -1.082 |
| March 31, 2020 | -0.999 |
| December 31, 2019 | -1.039 |
| September 30, 2019 | -1.094 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-1.094
Minimum
Sep 2019
0.8808
Maximum
Mar 2024
-0.1727
Average
--
Median
Jun 2021
Debt to Equity Ratio Benchmarks
| OptiNose Inc | -1.504 |
| Perspective Therapeutics Inc | 0.0229 |
| Dare Bioscience Inc | 0.00 |
| Kodiak Sciences Inc | -- |
| INmune Bio Inc | 0.2569 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 151.28M |
| Total Liabilities (Quarterly) | 102.46M |
| Shareholders Equity (Quarterly) | 48.82M |
| Current Ratio | 2.103 |
| Net Debt Paydown Yield | -2.49% |